FibroBiologics (NASDAQ: FBLG) ends sublease to save $0.8M rent

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

FibroBiologics, Inc. terminated its sublease for office space in Webster, Texas through a Sublease Buyout Agreement effective April 2, 2026, well before the original November 30, 2027 end date. The company made a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent.

The change follows FibroBiologics’ 2025 opening of a new state-of-the-art laboratory facility with over 10,000 square feet of lab and office space and supports its consolidation of operations. The company’s principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

8-K Event Classification

3 items: 1.01, 8.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Lease termination payment: $45,108.25 Expected rent savings: approximately $0.8 million Lab facility size: over 10,000 square feet +3 more

6 metrics

Lease termination payment $45,108.25 Single payment to resolve remaining rent obligations under sublease

Expected rent savings approximately $0.8 million Future rent savings from early sublease termination

Lab facility size over 10,000 square feet State-of-the-art laboratory and office space opened in 2025

Sublease termination date April 2, 2026 Effective date of Lease Termination Agreement

Original sublease expiration November 30, 2027 Initial end date of sublease before buyout

New principal office address 9350 Kirby Drive, Suite 300, Houston, TX 77054 Updated location of principal executive offices

Key Terms

Sublease Buyout Agreement, Lease Termination Agreement, Sublease Agreement, principal executive offices, +1 more

5 terms

Sublease Buyout Agreement financial

"entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”)"

Lease Termination Agreement financial

"entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”)"

Sublease Agreement financial

"terminate that certain Sublease Agreement, which was effective as of October 5, 2022"

principal executive offices regulatory

"The new address of the Company’s principal executive offices is 9350 Kirby Drive"

emerging growth company regulatory

"Emerging growth company Item 1.01 Entry into a Material Definitive Agreement."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

04/09/2026 - 04:15 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 03, 2026

    

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41934	86-3329066
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9350 Kirby Drive, Suite 300
Houston, Texas		77054
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 281 671-5150

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 par value	FBLG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598. The Lease Termination Agreement terminated the Sublease effective April 2, 2026, successfully concluding the Sublease well ahead of its original expiration date of November 30, 2027. The Company resolved its remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent payments.

This strategic consolidation follows the Company's 2025 opening of its state-of-the-art laboratory facility, encompassing over 10,000 square feet of dedicated lab and office space. By eliminating redundant office costs approximately 18 months ahead of schedule, the Company strengthens its operational efficiency and redirects resources toward its core mission of advancing fibroblast-based therapeutics.

Item 8.01 Other Events.

The new address of the Company’s principal executive offices is 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

Item 9.01 Financial Statements and Exhibits.


Exhibit 104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			FibroBiologics, Inc.

Date:	Apri 9, 2026	By:	/s/ Pete O'Heeron
			Name: Pete O'Heeron Title: Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What lease change did FibroBiologics (FBLG) disclose in this 8-K?

FibroBiologics terminated its sublease for space at 455 E. Medical Center Blvd in Webster, Texas. The Sublease Buyout Agreement ended the sublease effective April 2, 2026, which was well ahead of its original November 30, 2027 expiration date.

How much will FibroBiologics (FBLG) pay and save from the sublease termination?

FibroBiologics resolved its remaining rent obligations with a single payment of $45,108.25. By ending the sublease early, the company expects to save approximately $0.8 million in future rent payments, reducing ongoing office-related costs and supporting its operational consolidation.

Why is FibroBiologics consolidating office space according to the filing?

The company is consolidating after opening a state-of-the-art laboratory facility in 2025 with over 10,000 square feet of lab and office space. Ending the older sublease eliminates redundant office costs and allows more resources to be directed toward advancing fibroblast-based therapeutics.

What is the new principal executive office address for FibroBiologics (FBLG)?

FibroBiologics’ principal executive offices are now located at 9350 Kirby Drive, Suite 300, Houston, Texas 77054. This new address reflects the company’s post-consolidation headquarters location following the termination of its prior sublease in Webster, Texas.

How far ahead of schedule did FibroBiologics end its sublease?

The company ended its sublease effective April 2, 2026, compared with the original November 30, 2027 expiration date. This means the sublease was concluded roughly 18 months ahead of schedule, contributing to the expected rent savings noted in the filing.

Filing Exhibits & Attachments

1 document